Thought Leadership

Latest Report


Vantage Pharma, Biotech and Medtech 2018 in Review

Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong The Vantage 2018 in Review paints a mixed picture for biopharma and medtech in 2018. Key indicators on share price and dealmaking showed weakness, but there are signs of health from the industry in IPO outcomes, venture financing…

Report library


EvaluatePharma Orphan Drug Report 2018

Report Highlights Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 The mean price of the top 100 USA orphan drugs is expected to…


EP Vantage 2018 Preview

Report Highlights M&A activity expected to climb after slow 2017 – US tax reform a deciding factor for big deals Another big year predicted for venture financing…